ArticleNanotechnology, science and applications2025
Multimodal Nanobiophysical Profiling of Melanoma-Derived Small Extracellular Vesicles Reveals Glycan Signatures Associated with Tumor Progression.
Article in Nanotechnology, science and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Small extracellular vesicles (sEVs) are nanoscale biomaterial-like structures involved in intercellular communication and cancer progression. Aberrant surface glycosylation may serve as a diagnostic marker for malignancy. This study aimed to compare the size, glycosylation, and biophysical properties of sEVs secreted by primary and metastatic melanoma cells, and to evaluate a novel analytical technique for glycoprofiling. Methods: sEVs were isolated from the primary (WM115) and metastatic (WM266-4) melanoma cell lines. Their size and concentration were assessed via Nanoparticle Tracking Analysis (NTA), and exosomal identity was confirmed using Western blotting. Glycosylation profiling was performed using a multimodal strategy: Quartz Crystal Microbalance with Dissipation monitoring (QCM-D), Nanoplasmonic Sensing (NPS), and, for the first time, Flow-Induced Dispersion Analysis (FIDA). Concanavalin A (Con A) was used as the probe for high-mannose glycans. Results: WM266-4-derived sEVs were significantly larger, whereas WM115 cells secreted more vesicles. Western blotting confirmed the presence of exosomal markers and absence of organelle contaminants. QCM-D and NPS showed stronger Con A binding and higher glycan viscoelasticity index (gVI) in metastatic sEVs, indicating altered glycan architecture. FIDA further confirmed these differences by quantifying a lower dissociation constant (Kd) and multivalent binding behavior in WM266-4-derived sEVs, consistent with a denser glycan coat. Conclusion: Metastatic melanoma-derived sEVs exhibited distinct Con A-detectable high-mannose glycosylation patterns that may represent malignancy-associated features. This study demonstrates the utility of multimodal nanobiophysical methods, particularly FIDA, as sensitive tools for EV glycoprofiling. While the present findings are based on cell line-derived sEVs, they support the translational potential of glycan-based signatures for future liquid biopsy platforms and expand the analytical capabilities of cancer nanodiagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.